Hopes that the novel antibody-drug conjugate (ADC) camidanlumab tesirine (Cami) might soon secure a review under the Accelerated Approval scheme have been dashed.
Swiss biotech ADC Therapeutics (NYSE: ADCT) revealed that the US Food and Drug Administration had provided “strong guidance” that its confirmatory study must be “well underway,” for that to happen.
That is in line with signals given by the FDA, with Commissioner Robert Califf having indicated that the system is in line for some changes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze